What Heberprot-P Treats: Main Uses and Benefits

Heberprot-P is a specialized therapeutic product developed primarily for the management of complex wounds associated with metabolic disorders. Its application is focused on addressing tissue repair challenges that do not respond to standard care protocols.

Primary Indications

The medication is used for the treatment of advanced diabetic foot ulcers (DFU). It is specifically intended for patients with deep, high-grade ulcers that have penetrated through the skin layers to reach deeper tissues, such as tendons, ligaments, or bone. These types of wounds are often classified as Wagner Grade 3 or 4 ulcers.

Heberprot-P is typically integrated into a comprehensive wound management plan when traditional treatments, such as debridement and specialized dressings, are insufficient to stimulate the natural healing process.

Mechanism and Healing Benefits

The treatment works by utilizing recombinant human epidermal growth factor (rhEGF) to influence the cellular environment of the wound. The primary benefits observed during treatment include:

• Stimulation of Granulation Tissue: It promotes the formation of healthy, red granular tissue, which is essential for filling the wound bed and supporting new skin growth.
• Reduction in Healing Time: By accelerating the proliferative phase of wound healing, the medication can help close deep ulcers more quickly than standard therapies alone.
• Improvement in Wound Quality: The treatment helps transform chronic, stagnant wounds into active, healing ones by encouraging cell migration and collagen synthesis.

Clinical Objectives

The overarching goal of using Heberprot-P is to manage severe ulcerations that carry a high risk of complications. By stimulating effective tissue regeneration, the therapy aims to:

• Decrease the total area and depth of the ulcer.
• Prevent the progression of the wound to a state where surgical intervention, such as amputation, becomes the only remaining option.
• Provide a therapeutic pathway for patients with peripheral arterial disease or neuropathy whose healing capacity is naturally compromised.

Eligibility Map: Who Can and Cannot Use Heberprot-P

Populations for whom use is allowed (as stated in label):

• Adult diabetic patients with neuropathic and/or ischemic Diabetic Foot Ulcers (DFUs) greater than 1 cm².

Populations for whom use is contraindicated: Use is prohibited for patients with:

• History of hypersensitivity to the product.
• Acute cardiovascular events (e.g., myocardial infarction, stroke) in the previous three months.
• Severe congestive heart failure (NYHA Class III/IV), severe atrioventricular block, or uncontrolled atrial fibrillation.
• Acute metabolic states such as diabetic coma or diabetic ketoacidosis.

Eligibility-related restrictions:

• Malignancy Exclusion: Lesions suspected of malignancy require a biopsy to exclude a tumor before use.
• Renal Impairment: Use with caution in severe renal failure (creatinine greater than 200 μmol/L).
• Infection Status: Existing infections or osteomyelitis must be adequately treated prior to administration.

Age, Pregnancy, and Lactation Status:

• Pediatric patients and pregnant women have insufficient data to support use; a risk-benefit assessment is required.
• Use is not recommended for nursing mothers.

The official regulatory profile for Heberprot-P (active ingredient: Nepidermin, a recombinant human growth factor) documents a very limited interaction landscape. This profile is consistent with its route of administration as a localized, intralesional injection.

---

Documented Administration Restrictions

The primary constraint listed in official product labeling concerns the co-administration of Heberprot-P with other local treatments.

Interaction Category	Official Regulatory Statement
Topical Products	It is not known if Heberprot-P interacts with other topical medications.
Administration Restriction	Due to the unknown interaction status, the medicine must not be applied simultaneously with other topical products or local medications.

---

Systemic and Pharmacokinetic Interactions

The regulatory documentation for Nepidermin does not report any clinically significant systemic drug-drug interactions.

Interaction Type	Status in Regulatory Documents
Metabolic Interactions	No information is documented regarding interactions mediated by cytochrome P450 (CYP) enzymes.
Pharmacodynamic Interactions	No specific additive or synergistic effects with other medicinal products are formally documented.
Food, Alcohol, or Supplements	No interactions with food, alcohol, or herbal supplements are documented.

---

The interaction structure is defined by the sole administration-site restriction, while data concerning systemic exposure-modifying effects or transporter-mediated interactions are absent from the official profile.

How Heberprot-P Works

Targeting the Epidermal Growth Factor Receptor ( EGFR)

The drug's mechanism initiates at the molecular level with its active component, recombinant human Epidermal Growth Factor ( rhEGF), which acts as an agonist by binding directly to the EGFR on cell surfaces. This specific binding activates signal transduction pathways inside cells, such as MAPK/ERK and PI3K/AKT, which are involved in the regulation of cellular growth.

Modulating Cell Proliferation and Tissue Synthesis

Activating these pathways drives the physiological process of mitogenesis (cell division) and migration for skin cells (keratinocytes) and connective tissue cells (fibroblasts). This mechanism modulates the local synthesis of structural components like collagen and contributes to the development of the cellular environment that precedes tissue formation.

Inducing Angiogenesis and Vascular Support

The drug's action also indirectly supports the formation of a functional blood supply through angiogenesis. By encouraging the local secretion of pro-growth factors ( VEGF), the mechanism stimulates the development of new blood vessels, which supports perfusion (blood flow), oxygen, and nutrient delivery to the newly developing tissue matrix.

How to use Heberprot-P

The official use of Heberprot-P follows a precise, standardized administration protocol designed for application within a comprehensive wound management plan. The medicine is classified as a prescription product and must be administered exclusively by trained medical personnel.

Administration Protocol Summary

Entity	Official Administration Guidelines
Route of Administration	The medicine is administered as an intralesional injection, meaning it is carefully infiltrated directly into the tissue defect and surrounding edges.
Dosing and Schedule	The standardized dose is 75 µg of Nepidermin, administered on a fixed schedule of three times per week.
Preparation Requirements	Prior to injection, the lyophilized 75 µg product must be reconstituted with 5 mL of water for injection and administered immediately after preparation.
Use-Context Constraints	Administration is mandated to be used concurrently with good standard wound care, which includes necessary debridement, pressure relief, and proper management of any existing infection before treatment begins.
Course Duration	Treatment is designed as a finite course, maintained until the desired clinical outcome of complete granulation tissue coverage or wound closure is achieved, or until a maximum duration of eight weeks is reached. Treatment is discontinued if the ulcer area is reduced to less than 1 cm^2.

---

Use Protocol Overview

The treatment course is governed by a goal-oriented time limit, ensuring the medicine is used for a defined period based on clinical response, rather than indefinitely. The administration method is a local, intermittent injection that requires specific preparation steps immediately prior to use. This entire procedural structure emphasizes that Heberprot-P functions as an adjunctive treatment within a larger, comprehensive wound care strategy overseen by specialists.

Heberprot-P: Recent Clinical Evidence

---

The Clinical Research Base

The research on Heberprot-P, which contains the active ingredient Nepidermin (recombinant human epidermal growth factor or rhEGF), has been concentrated on its evaluation in chronic, non-healing Diabetic Foot Ulcers (DFUs). The evidence base primarily includes Randomized Controlled Trials (RCTs), as well as scientific reviews and meta-analyses that combine data from multiple related trials. These studies were designed to examine outcomes related to the tissue repair process. Researchers specifically tracked measures like the percentage of patients achieving complete wound closure (full re-epithelialization), the time required for closure, the formation of granulation tissue, and amputation rates across the study groups. Findings describe patterns observed in these specific measures of recovery.

---

Follow-up, Populations, and Limitations

Clinical trials typically monitored adult patients with full-thickness lower extremity ulcers, with a specific focus on advanced severity (Wagner Grades 2, 3, and 4). The typical follow-up period extends to around 52 weeks (one year), during which researchers track the rate of ulcer recurrence. Research noted a specific focus on these severe ulcers, but findings describe patterns observed only within the specific populations studied. Subgroup findings for patients with very specific comorbidities, such as advanced peripheral artery disease, remain less defined.

Several uncertainties and limitations remain within the evidence base. Long-term effects are not fully established, as consistent, multi-year recurrence data are limited. Additionally, variability exists due to some studies using a topical application of rhEGF, while the regulatory documentation for Heberprot-P specifies intralesional injection, leading to some heterogeneity in the evidence. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain—about this treatment.

Common questions about Heberprot-P (FAQ)

Q: Is Heberprot-P available in the United States?

A: According to official sources, this medicine is currently authorized for marketing and use in 26 countries outside the United States. It is not yet approved by the U.S. FDA for commercial use, but it is currently authorized and undergoing a Phase 3 clinical trial within the country.

Q: How is Heberprot-P different from standard wound care methods?

A: Heberprot-P is a specialized recombinant biological product that works by providing a biological stimulus directly into the wound tissue. This intralesional injection method is distinct from standard wound care practices—such as wound cleaning and pressure relief—which are mandated to be used at the same time as the medicine.

Q: Can Heberprot-P be used on wounds other than diabetic foot ulcers?

A: The official indication for this medicine has been established for chronic, non-healing diabetic foot ulcers (DFUs). Current research is described as exploring new formulations for use in other complex, non-healing wounds such as pressure sores, but the primary use remains focused on DFUs.

Q: Is this medicine approved by major global regulatory bodies?

A: This medicine is authorized for marketing by the regulatory authorities in 26 countries around the world. Major regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have not yet granted commercial approval.

Q: Can elderly patients use Heberprot-P?

A: Official information indicates that use of this medicine is not prohibited based on age alone. Contraindications are based on specific pre-existing conditions, such as recent cardiovascular events or severe heart failure, rather than general geriatric status.

Q: Are there studies comparing Heberprot-P to other topical wound treatments?

A: Clinical trials and evidence reviews do include studies that evaluate the active ingredient ( recombinant human epidermal growth factor) against other topical treatments. These studies provide context on the drug's effects, although official regulatory documentation specifies the use of the unique intralesional injection method.

Q: What happens to the wound after treatment with Heberprot-P is finished?

A: Treatment is maintained until the goal of complete granulation tissue coverage or wound closure is achieved, or up to a maximum of eight weeks. Following treatment completion, studies describe a typical follow-up period (e.g., one year) to monitor for the potential recurrence of the ulcer.

Q: Does using Heberprot-P affect blood sugar levels in diabetic patients?

A: Official product information notes that the medicine contains sucrose as an inactive component. Because of this, it may have an impact on the glycaemic control (blood sugar management) of patients with diabetes, and adverse events related to metabolic control are monitored.

Q: Is Heberprot-P used in combination with surgery?

A: The administration protocol mandates that this medicine must be used concurrently with good standard wound care. This care includes necessary debridement and proper management of infection, which are often procedures or surgical interventions performed by a specialist.

Q: What kind of specialist usually prescribes Heberprot-P?

A: Regulatory documentation states that the treatment must be administered exclusively by trained medical personnel. The official warnings specify that the treatment should be performed by medical practitioners experienced in managing diabetic foot ulcers.

Q: What is the shelf life or stability of Heberprot-P?

A: The lyophilized (freeze-dried) medicine has a documented shelf life of 36 months when kept under refrigerated storage conditions (2 C to 8 C). The medicine must be administered immediately after it is mixed with water into a solution.

Q: Is the use of Heberprot-P limited to a specific stage of wound healing?

A: The medicine is intended for chronic, advanced tissue defects where healing has stalled. Its primary action is to stimulate the proliferation and migration of cells and encourage the formation of granulation tissue, which are processes vital to the later stages of wound repair.

Q: What research is currently ongoing about Heberprot-P?

A: Research is ongoing, including Phase 3 clinical trials currently authorized and underway in the United States. Other research is described as exploring the use of new formulations for the treatment of additional complex chronic wounds beyond diabetic foot ulcers.

Q: Does Heberprot-P contain any animal products?

A: The active ingredient, recombinant human epidermal growth factor (rhEGF), is produced using biotechnological methods. Specifically, the manufacturing process uses a Saccharomyces cerevisiae yeast line, which is a fungal organism, not an animal source.

Q: Are there specific dressing materials recommended with Heberprot-P?

A: The official administration protocol specifies the use of occlusive bandages (dressings that seal or prevent passage of air/fluid) over the treated wound area after the intralesional injection has been performed.

Q: Do patients with peripheral arterial disease qualify for Heberprot-P?

A: Regulatory warnings address patients who have ischaemia (poor blood flow) due to severe peripheral macroangiopathy. For such vascular issues, official product information indicates that a reperfusion procedure (a procedure to restore blood flow to the limb) is required before starting treatment.

Storage and Disposal of Heberprot-P

To maintain the stability of the active ingredient, the lyophilized Heberprot-P product must be kept under refrigerated storage conditions. This is defined as a temperature range between 2°C and 8°C, and the product must not be frozen. It must also be stored protected from light and kept out of the sight and reach of children.

---

Once the medicine is reconstituted into a solution, the product must be administered immediately. Unused or expired Heberprot-P should be disposed of in accordance with local and national regulations for pharmaceutical waste, and it should not be discarded in wastewater or household trash.